Literature DB >> 19403848

Locally advanced rectal cancer: MR imaging for restaging after neoadjuvant radiation therapy with concomitant chemotherapy. Part II. What are the criteria to predict involved lymph nodes?

Max J Lahaye1, Geerard L Beets, Sanne M E Engelen, Alfons G H Kessels, Adriaan P de Bruïne, Herry W S Kwee, Jos M A van Engelshoven, Cornelis J H van de Velde, Regina G H Beets-Tan.   

Abstract

PURPOSE: To prospectively determine diagnostic performance of predictive criteria for nodal restaging after radiation therapy with concomitant chemotherapy by using ultrasmall superparamagnetic iron oxide (USPIO)-enhanced magnetic resonance (MR) imaging in patients with rectal cancer.
MATERIALS AND METHODS: After institutional review board approval and informed consent were obtained, 39 patients (24 men, 15 women; mean age, 64 years) with rectal cancer underwent USPIO-enhanced two-dimensional (2D) T2-weighted fast spin-echo, three-dimensional (3D) T1-weighted gradient-echo, and 3D T2*-weighted MR for restaging. Two observers evaluated nodes for border irregularity, short- and long-axis diameters, and estimated percentage of white region (<30%, 30%-50%, or >50%) within the node (3D T2*-weighted images). Ratio of the measured surface area of the white region within the black node to the measured surface area of the total node (Ratio(A)) was calculated. Signal intensity (SI) in gluteus muscle (SI(GM)) and in total node (SI(TN)) were used to calculate SI(TN)/SI(GM) ratio. Histopathologic findings were reference standard. Receiver operating characteristic (ROC) curves were compared and interobserver agreement was determined.
RESULTS: Lesion-by-lesion analysis was feasible in 201 lymph nodes. Area under the ROC curve (AUC) of border and short- and long-axis diameters for observer 1 were 0.85, 0.87, and 0.88 and for observer 2 were 0.70, 0.89, and 0.87, respectively. AUC for estimated percentage of white region within the node, Ratio(A), and SI(TN)/SI(GM) ratio for observer 1 were 0.98, 0.99, and 0.62 and for observer 2 were 0.97, 0.98, and 0.65, respectively. AUC for USPIO-enhanced MR criteria was significantly better than AUC for conventional MR criteria (P < .01). All criteria except border irregularity and SI(TN)/SI(GM) ratio showed high interobserver agreement (kappa > 0.79).
CONCLUSION: The most reliable predictors for identifying benign nodes after radiation therapy with concomitant chemotherapy by using USPIO-enhanced MR imaging for restaging in patients with rectal cancer were estimated percentage of white region within the node and Ratio(A). Measurements on standard 2D T2-weighted fast spin-echo images versus primary staging results offer reasonably good accuracy to identify benign lymph nodes after therapy. (c) RSNA, 2009.

Entities:  

Mesh:

Year:  2009        PMID: 19403848     DOI: 10.1148/radiol.2521081364

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  32 in total

1.  A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial.

Authors:  Julio Garcia-Aguilar; Qian Shi; Charles R Thomas; Emily Chan; Peter Cataldo; Jorge Marcet; David Medich; Alessio Pigazzi; Samuel Oommen; Mitchell C Posner
Journal:  Ann Surg Oncol       Date:  2011-07-14       Impact factor: 5.344

2.  Locally advanced rectal cancer: is diffusion weighted MRI helpful for the identification of complete responders (ypT0N0) after neoadjuvant chemoradiation therapy?

Authors:  S Sassen; M de Booij; M Sosef; R Berendsen; G Lammering; R Clarijs; M Bakker; R Beets-Tan; F Warmerdam; R Vliegen
Journal:  Eur Radiol       Date:  2013-07-06       Impact factor: 5.315

3.  Clinical significance of magnetic resonance imaging findings in rectal cancer.

Authors:  Charles F Bellows; Bernard Jaffe; Lorenzo Bacigalupo; Salvatore Pucciarelli; Guiseppe Gagliardi
Journal:  World J Radiol       Date:  2011-04-28

Review 4.  The use of PET/MRI for imaging rectal cancer.

Authors:  Thomas A Hope; Zahra Kassam; Andreas Loening; Michelle M McNamara; Raj Paspulati
Journal:  Abdom Radiol (NY)       Date:  2019-11

5.  Quantitative analysis and prediction of regional lymph node status in rectal cancer based on computed tomography imaging.

Authors:  Chunyan Cui; Hongmin Cai; Lizhi Liu; Liren Li; Haiying Tian; Li Li
Journal:  Eur Radiol       Date:  2011-06-29       Impact factor: 5.315

6.  Diffusion-weighted MR imaging in primary rectal cancer staging demonstrates but does not characterise lymph nodes.

Authors:  Luc A Heijnen; Doenja M J Lambregts; Dipanjali Mondal; Milou H Martens; Robert G Riedl; Geerard L Beets; Regina G H Beets-Tan
Journal:  Eur Radiol       Date:  2013-07-03       Impact factor: 5.315

7.  Pelvic MRI after induction chemotherapy and before long-course chemoradiation therapy for rectal cancer: What are the imaging findings?

Authors:  Marc J Gollub; Ivana Blazic; David D B Bates; Naomi Campbell; Andrea Knezevic; Mithat Gonen; Patricio Lynn; Martin R Weiser; Julio Garcia-Aguilar; Andreas M Hötker; Andrea Cercek; Leonard Saltz
Journal:  Eur Radiol       Date:  2018-10-02       Impact factor: 5.315

8.  Role of tumor size in the pre-operative management of rectal cancer patients.

Authors:  Inti Zlobec; Parham Minoo; Eva Karamitopoulou; George Peros; Efstratios S Patsouris; Frank Lehmann; Alessandro Lugli
Journal:  BMC Gastroenterol       Date:  2010-06-15       Impact factor: 3.067

9.  MRI for evaluation of treatment response in rectal cancer.

Authors:  Ivana M Blazic; Naomi M Campbell; Marc J Gollub
Journal:  Br J Radiol       Date:  2016-06-22       Impact factor: 3.039

10.  Multimodal preoperative evaluation system in surgical decision making for rectal cancer: a randomized controlled trial.

Authors:  Xiaodong Wang; Donghao Lv; Huan Song; Lei Deng; Qiang Gao; Junhua Wu; Yingyu Shi; Li Li
Journal:  Int J Colorectal Dis       Date:  2010-03       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.